Evidence map›Paper›PMID 37126534›Full record

ArticlePLoS pathogens2023

Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike.

Xiaodi Yu, Jarek Juraszek, Lucy Rutten, Mark J G Bakkers, Sven Blokland, Jelle M Melchers, Niels J F van den Broek, Annemiek Y W Verwilligen, Pravien Abeywickrema, Johan Vingerhoets and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Xiaodi YuStructural & Protein Sciences, Janssen Research and Development, Spring House, Pennsylvania, United States of America.ORCID 0000-0001-7520-0646
Jarek JuraszekJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Lucy RuttenJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Mark J G BakkersJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Sven BloklandJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Jelle M MelchersJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Niels J F van den BroekJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Annemiek Y W VerwilligenJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Pravien AbeywickremaStructural & Protein Sciences, Janssen Research and Development, Spring House, Pennsylvania, United States of America.
Johan VingerhoetsJanssen Pharmaceutica N.V., Clinical Microbiology and Immunology, Beerse, Belgium.
Jean-Marc NeefsJanssen Pharmaceutica N.V., Discovery Sciences, Beerse, Belgium.
Shah A Mohamed BakhashDepartment of Laboratory Medicine and Pathology, Virology Division, University of Washington, Seattle, Washington, United States of America.
Pavitra RoychoudhuryDepartment of Laboratory Medicine and Pathology, Virology Division, University of Washington, Seattle, Washington, United States of America.
Alex GreningerDepartment of Laboratory Medicine and Pathology, Virology Division, University of Washington, Seattle, Washington, United States of America.
Sujata SharmaStructural & Protein Sciences, Janssen Research and Development, Spring House, Pennsylvania, United States of America.
Johannes P M LangedijkJanssen Vaccines & Prevention BV, Leiden, the Netherlands.ORCID 0000-0001-8768-0982
Janssen (Netherlands) · NLSpringhouse · USUniversity of Washington · USJanssen (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global spread of the SARS-CoV-2 virus has resulted in emergence of lineages which impact the effectiveness of immunotherapies and vaccines that are based on the early Wuhan isolate. All currently approved vaccines employ the spike protein S, as it is the target for neutralizing antibodies. Here we describe two SARS-CoV-2 isolates with unusually large deletions in the N-terminal domain (NTD) of the spike. Cryo-EM structural analysis shows that the deletions result in complete reshaping of the NTD supersite, an antigenically important region of the NTD. For both spike variants the remodeling of the NTD negatively affects binding of all tested NTD-specific antibodies in and outside of the NTD supersite. For one of the variants, we observed a P9L mediated shift of the signal peptide cleavage site resulting in the loss of a disulfide-bridge; a unique escape mechanism with high antigenic impact. Although the observed deletions and disulfide mutations are rare, similar modifications have become independently established in several other lineages, indicating a possibility to become more dominant in the future. The observed plasticity of the NTD foreshadows its broad potential for immune escape with the continued spread of SARS-CoV-2.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralDisulfidesHumansImmunotherapySARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralDisulfidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID37126534
PMCPMC10174534
OpenAlexW4367601343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.